CAR-T cells and BiTEs in solid tumors: challenges and perspectives
Abstract Chimeric antigen receptor (CAR)-modified T cells and BiTEs are both immunotherapies which redirect T cell specificity against a tumor-specific antigen through the use of antibody fragments. They demonstrated remarkable efficacy in B cell hematologic malignancies, thus paving the way for the...
Main Authors: | Julien Edeline, Roch Houot, Aurélien Marabelle, Marion Alcantara |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-04-01
|
Series: | Journal of Hematology & Oncology |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13045-021-01067-5 |
Similar Items
-
Generation of dual specific bivalent BiTEs (dbBIspecific T-cell engaging antibodies) for cellular immunotherapy
by: Maciej Kujawski, et al.
Published: (2019-09-01) -
Harnessing T Cells to Target Pediatric Acute Myeloid Leukemia: CARs, BiTEs, and Beyond
by: Rebecca Epperly, et al.
Published: (2020-02-01) -
BiTEs, DARTS, BiKEs and TriKEs—Are Antibody Based Therapies Changing the Future Treatment of AML?
by: Cecily Allen, et al.
Published: (2021-05-01) -
The Agony of Choice—Where to Place the Wave of BCMA-Targeted Therapies in the Multiple Myeloma Treatment Puzzle in 2022 and Beyond
by: Irene Strassl, et al.
Published: (2021-09-01) -
Bispecific Antibodies as a Development Platform for New Concepts and Treatment Strategies
by: Fa Yang, et al.
Published: (2016-12-01)